Wiley Matthew T. sold $129K of DFTX

Wiley Matthew T. (Chief Commercial Officer) sold 2,867 shares of Definium Therapeutics, Inc. (DFTX) at $45.03 ($0.13M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wiley Matthew T.
Published Jun 26, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Neutral
high confidence
Mentioned
$DFTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not introduce new company-specific fundamentals or events.

02

Market read

Traders may monitor for follow-on insider activity, but this specific transaction is unlikely to drive a material repricing without additional catalysts.

03

What to watch

The filing does not state any change in company guidance, trial status, or financing; traders should avoid extrapolating fundamentals from a planned sale.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-26 after-hours; reflects sale executed 2026-06-25.

Background

The article is an SEC Form 4 insider transaction disclosure for Definium Therapeutics, Inc.

Company-level read

Ticker impact

$DFTXNeutralHigh confidence
Context

Definium Therapeutics CCO Wiley Matthew T. sold 2,867 shares in an open-market transaction at $45.03 on 2026-06-25 under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely limited to sentiment/flow rather than a new catalyst.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and it discloses no new operating, regulatory, or financial datapoint beyond the sale details.

Market effects

No sector read-across; single-company insider sale with no disclosed business change.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may be mechanically scheduled and not a signal of deteriorating outlook.

Key entities

  • Definium Therapeutics, Inc.

    Subject of the Form 4 insider transaction; CCO sold shares under a 10b5-1 plan.

  • Wiley Matthew T.

    Chief Commercial Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT